Lawsuit comes after Friday's announcement that the NIH would limit the indirect costs it will pay grantees to 15 percent of a grant.

Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases ...

After a slow 2024, dealmaking in the U.S. healthcare sector is picking up. Springworks has a market value of $3 billion.

A small but growing number of house cats have gotten sick from H5N1, the bird flu strain driving the current U.S. outbreak.

SpringWorks Therapeutics shares rose 36% after Reuters reported Germany's Merck KGaA is in advanced talks to buy the company. Shares were trading around $54.66. The stock is up 16% over the last year ...

Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases ...

-- Germany's Merck KGaA is in advanced talks to buy U.S. cancer and rare diseases biotech company Springworks Therapeutics, Reuters says, citing unnamed sources. -- The deal could be finalized in the ...

Springworks, which listed its shares in New York in 2019, is a commercial-stage biotech firm that develops drugs to treat various forms of cancer and other rare diseases such as uterine cancer and ...

GeneDx has a big market in mind for its genetic testing: every newborn baby. The 24-year-old-company wants to make the testing common at birth. The goal: Identify potential diseases or conditions so ...

Eli Lilly has been a terrific stock to own for the past five years, thanks to its excellent clinical and regulatory progress. The company's breakthroughs are paying off. In each of the past six ...